Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma.

ABSTRACT:

Background

Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the views of patients with early-stage melanoma on the acceptability of the test and early treatment.

Methods

A qualitative cross-sectional design using one-to-one semi-structured telephone interviews was employed. Twenty-five patients diagnosed with early-stage melanoma (Stage IA-IIC) were asked for their views on ctDNA monitoring and early treatment for relapse. Interviews were analysed using reflexive thematic analysis.

Results

Two themes were generated: ctDNA monitoring wou

SUBMITTER: Woof VG 

PROVIDER: S-EPMC8927744 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature